Bajaj Housing Finance Limited (BOM:544252)

Marinus Pharmaceuticals Income Statement

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun 30, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Operating Revenue	2,194	2,340	1,907	1,365	2,239	2,168
Other Revenue	97,189	92,941	73,886	55,161	35,407	29,379
Revenue	99,383	95,282	75,794	56,526	37,646	31,546
Revenue Growth (YoY)	23.97%	25.71%	34.09%	50.15%	19.34%	19.22%
Cost of Revenue	6,285	5,750	5,369	5,720	5,347	5,014
Gross Profit	93,098	89,531	70,425	50,806	32,299	26,532
Selling, General & Admin	93.5	93.5	110.5	105.3	60.5	68.7
Other Operating Expenses	1,712	1,499	1,360	1,242	825.4	450.7
Operating Expenses	2,229	2,004	1,866	1,681	1,144	737.1
Operating Income	90,870	87,527	68,559	49,125	31,156	25,795
Interest Expense	-61,865	-59,793	-46,926	-32,113	-21,553	-19,615
Interest & Investment Income	-	-	-	3	1	3.7
Other Non Operating Income (Expenses)	-4.8	-4.8	-11.9	-6.9	-	-47.3
EBT Excluding Unusual Items	29,000	27,730	21,621	17,008	9,603	6,136
Gain (Loss) on Sale of Assets	-27.2	-27.2	-7.7	-7	-4.8	-4.4
Pretax Income	28,973	27,702	21,613	17,001	9,599	6,132
Income Tax Expense	6,337	6,073	4,301	4,423	2,502	1,600
Net Income	22,636	21,629	17,312	12,578	7,096	4,532
Net Income to Common	22,636	21,629	17,312	12,578	7,096	4,532
Net Income Growth	29.20%	24.93%	37.64%	77.25%	56.58%	7.56%
Shares Outstanding (Basic)	8,229	8,092	6,712	6,682	4,883	4,883
Shares Outstanding (Diluted)	8,236	8,099	6,712	6,682	4,883	4,883
Shares Change (YoY)	17.94%	20.66%	0.45%	36.84%	-	30.08%
EPS (Basic)	2.75	2.67	2.58	1.88	1.45	0.93
EPS (Diluted)	2.75	2.67	2.58	1.88	1.45	0.93
EPS Growth	10.08%	3.52%	37.02%	29.54%	56.58%	-17.14%
Free Cash Flow	-	-170,999	-146,258	-143,521	-124,989	-50,824
Free Cash Flow Per Share	-	-21.11	-21.79	-21.48	-25.59	-10.41
Gross Margin	93.68%	93.97%	92.92%	89.88%	85.80%	84.10%
Operating Margin	91.43%	91.86%	90.45%	86.91%	82.76%	81.77%
Profit Margin	22.78%	22.70%	22.84%	22.25%	18.85%	14.37%
Free Cash Flow Margin	-	-179.47%	-192.97%	-253.90%	-332.01%	-161.11%
EBITDA	91,017	87,675	68,719	49,253	31,260	25,890
EBITDA Margin	91.58%	92.02%	90.67%	87.13%	83.04%	82.07%
D&A For EBITDA	147.28	147.9	160.4	128.3	104.6	95.1
EBIT	90,870	87,527	68,559	49,125	31,156	25,795
EBIT Margin	91.43%	91.86%	90.45%	86.91%	82.76%	81.77%
Effective Tax Rate	21.87%	21.92%	19.90%	26.01%	26.07%	26.09%
Revenue as Reported	99,857	95,760	76,177	56,654	37,671	31,553

Updated Jan 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.